# Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy

> **NCT03876938** · PHASE3 · UNKNOWN · sponsor: **Mahidol University** · enrollment: 147 (estimated)

## Conditions studied

- Antiemetic for Highly Emetogenic Chemotherapy

## Interventions

- **DRUG:** aprepitant
- **DRUG:** olanzapine 10 mg
- **DRUG:** olanzapine 5 mg

## Key facts

- **NCT ID:** NCT03876938
- **Lead sponsor:** Mahidol University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-01
- **Primary completion:** 2020-08
- **Final completion:** 2020-12
- **Target enrollment:** 147 (ESTIMATED)
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03876938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03876938, "Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03876938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*